Magnesium Hydroxide

Identification

Name
Magnesium Hydroxide
Accession Number
DB09104
Type
Small Molecule
Groups
Approved
Description

Magnesium hydroxide is an inorganic compound with the chemical formula Mg(OH)2. It is naturally found as the mineral brucite. Magnesium hydroxide can be used an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke supressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as an antiperspirant underarm deodorant or for relief of canker sores (aphthous ulcers).

Structure
Thumb
Synonyms
  • Magnesium dihydroxide
  • Milk of magnesia
External IDs
E-528 / INS NO.528 / INS-528
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Careone Milk Of MagnesiaSuspension1200 mg/15mLOralAmerican Sales Company2012-08-05Not applicableUs
Careone Milk Of MagnesiaSuspension1200 mg/15mLOralAmerican Sales Company2012-08-26Not applicableUs
Careone Milk Of MagnesiaSuspension1200 mg/15mLOralAmerican Sales Company2012-07-27Not applicableUs
Dermagran II Ointment - 0.25%Ointment.25 %TopicalTrans Canaderm Inc.1996-01-011996-09-10Canada
Dermagran II Ointment 0.25%Ointment.25 %TopicalCanadian Medical Supply Inc.1993-12-311996-09-09Canada
Dermagran II Ointment-ont Top 0.25%Ointment0.25 %TopicalCanderm G.P.1998-05-072008-08-06Canada
Dg Health Milk Of MagnesiaSuspension1200 mg/15mLOralDolgencorp2014-05-07Not applicableUs
Equaline Milk Of MagnesiaSuspension1200 mg/15mLOralSupervalu2005-11-14Not applicableUs
Equaline milk of magnesiaSuspension1200 mg/15mLOralSupervalu2004-10-14Not applicableUs
Equaline Milk Of MagnesiaSuspension1200 mg/15mLOralSupervalu2004-10-14Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acid Controller CompleteMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-05Not applicableUs
Acid Controller CompleteMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-05Not applicableUs
Acid Controller CompleteMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralSafeway2008-08-06Not applicableUs
Acid Controller Complete dual actionMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralWalgreen2008-07-30Not applicableUs
Acid Controller Complete dual actionMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralWalgreen2008-07-30Not applicableUs
Acid Reducer CompleteMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Acid Reducer CompleteMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-06Not applicableUs
Acid Reducer CompleteMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralRite Aid2009-05-15Not applicableUs
Acid Reducer CompleteMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Acid Reducer CompleteMagnesium Hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-12Not applicableUs
Categories
UNII
NBZ3QY004S
CAS number
1309-42-8
Weight
Average: 58.32
Monoisotopic: 57.990521206
Chemical Formula
H2MgO2
InChI Key
VTHJTEIRLNZDEV-UHFFFAOYSA-L
InChI
InChI=1S/Mg.2H2O/h;2*1H2/q+2;;/p-2
IUPAC Name
magnesium(2+) ion dihydroxide
SMILES
[OH-].[OH-].[Mg++]

Pharmacology

Indication

Magnesium hydroxide can be used as an antacid or a laxative depending on the administered dose.

As an antacid, it is used for the temporary relief of heartburn, upset stomach, sour stomach or acid indigestion.

As a laxative, it is used for the relief of occasional constipation by promoting bowel movements for 30 minutes and up to 6 hours.

Structured Indications
Pharmacodynamics

As an antacid, magnesium hydroxide suspension neutralizes gastric acid by reacting with hydrochloric acid in the stomach to form magnesium chloride and water. It is practically insoluble in water and does not have any effect until it reacts with the hydrochloric acid in the stomach. There, it decreases the direct acid irritant effect and increases the pH in the stomach leading to inactivation of pepsin. Magnesium hydroxide enhances the integrity of the mucosal barrier of the stomach as well as improving the tone of both the gastric and esophageal sphincters.

As a laxative, the magnesium hydroxide works by increasing the osmotic effect in the intestinal tract and drawing water in. This creates distension of the colon which results in an increase in peristaltic movement and bowel evacuation.

Mechanism of action

The suspension of magnesium hydroxide is ingested and enters the stomach. According to the amount ingested, the magnesium hydroxide will either act as an antacid or a laxative.

Through the ingestion of 0.5-1.5 grams (in adults) the magnesium hydroxide will act by simple acid neutralization in the stomach. The hydroxide ions from the magnesium hydroxide suspension will combine with the acidic H+ ions of the hydrochloric acid made by the stomachs parietal cells. This neutralization reaction will result in the formation of magnesium chloride and water.

Through the ingestion of 2-5 grams (in adults) the magnesium hydroxide acts as a laxative in the colon. The majority of the suspension is not absorbed in the intestinal tract and will create an osmotic effect to draw water into the gut from surrounding tissues. With this increase of water in the intestines, the feces will soften and the intraluminal volume of the feces will increase. These effects still stimulate intestinal motility and induce the urge to defecate. Magnesium hydroxide will also release cholecystokinin (CKK) in the intestines which will accumulate water and electrolytes in the lumen and furthermore increase intestinal motility.

Absorption

About 15%-50% of magnesium hydroxide is absorbed very slowly through the small intestine.

Volume of distribution

The peak action and distribution of magnesium hydroxide are variable.

Protein binding

Magnesium hydroxide does not have any protein binding properties.

Metabolism

Unless a patient is deficient in magnesium, very little is absorbed by the intestine. Overall, about 15%-50% of the magnesium hydroxide suspension is absorbed systemically. However, it does not undergo any metabolism as it is rapidly excreted in the urine.

Route of elimination

After oral administration, up to 50% of the magnesium hydroxide suspension may be absorbed as magnesium ions through the small intestines and then rapidly excreted in the urine through the kidneys. The unabsorbed drug is mainly excreted in the feces and saliva.

Half life

N/A

Clearance

Magnesium hydroxide is mainly excreted in the urine by the kidneys. Since the kidneys play a major role in its clearance, individuals with renal failure are at risk of hypermagnesemia with long term consumption as the appropriate amounts of magnesium may not be excreted.

Toxicity

LD50=8500 mg/kg (rat, oral)

Common side effects include drowsiness or flushing (warmth, redness or tingly feeling).

Daily use of magnesium hydroxide can result in fluid and electrolyte disturbances.

Excessive use of the laxative effects of magnesium hydroxide may result in abdominal cramping, nausea and/or diarrhea.

In overdose, symptoms of gastrointestinal irritation and/or watery diarrhea may occur.

Magnesium hydroxide poisoning can result in hypermagnesemia which includes symptoms of: nausea, vomiting, flushing, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, muscle weakness, respiratory depression, cardiac arrhythmias, coma and cardiac arrest.

Not to be used in individuals with any form of kidney disease or renal failure, a magnesium restricted diet or with any sudden changes in bowel movement lasting over two weeks. Also not to be used in those individuals with abdominal pain, nausea, vomiting, symptoms of appendicitis or myocardial damage, heart block, fecal impaction, rectal fissures, intestinal obstruction or perforation or renal disease. Not to be used in women who are about to deliver as magnesium crosses the placenta and is excreted in small amounts in breast milk.

Using magnesium hydroxide with aluminum hydroxide can decrease the absorption rate of these drugs.

Magnesium hydroxide can react with digoxin, dicoumerol and cimetidine.

Use of ibuprofen with magnesium hydroxide can increase the absorption of the ibuprofen.

Use of magnesium hydroxide with penicallamine, bisphosphates, ketoconazole, quinolones or tetracycline can decrease the absorption of these drugs.

Enteric-coated tablets can be prematurely released when taken with magnesium hydroxide.

It is important to routinely monitor levels of serum magnesium and potassium in patients using magnesium hydroxide. Serum magnesium levels are necessary to determine how much magnesium is being absorbed and how much is being excreted by the kidneys. Excessive diarrhea can occur from use of magnesium hydroxide and thus it is important to also monitor serum potassium levels to ensure hypokalemia does not occur.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium Hydroxide.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Hydroxide.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineMagnesium Hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineMagnesium Hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMagnesium Hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Magnesium Hydroxide.Experimental, Illicit
AcepromazineMagnesium Hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineMagnesium Hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium Hydroxide.Approved
AlcuroniumMagnesium Hydroxide may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magnesium Hydroxide.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Hydroxide.Approved
AlfacalcidolThe serum concentration of Magnesium Hydroxide can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AlimemazineMagnesium Hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolMagnesium Hydroxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magnesium Hydroxide.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium Hydroxide.Approved
AmphetamineMagnesium Hydroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium Hydroxide.Approved
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Magnesium Hydroxide.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Magnesium Hydroxide.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Magnesium Hydroxide.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Magnesium Hydroxide.Investigational
AtazanavirMagnesium Hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
AtracuriumMagnesium Hydroxide may increase the neuromuscular blocking activities of Atracurium.Experimental
Atracurium besylateMagnesium Hydroxide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Magnesium Hydroxide.Approved
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Magnesium Hydroxide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Magnesium Hydroxide.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium Hydroxide.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Magnesium Hydroxide.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Magnesium Hydroxide.Approved
BenzphetamineMagnesium Hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium Hydroxide.Approved, Withdrawn
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magnesium Hydroxide.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium Hydroxide.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Magnesium Hydroxide.Approved
BL-1020Magnesium Hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium Hydroxide.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium Hydroxide.Approved
CalcitriolThe serum concentration of Magnesium Hydroxide can be increased when it is combined with Calcitriol.Approved, Nutraceutical
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Magnesium Hydroxide.Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Magnesium Hydroxide.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Magnesium Hydroxide.Experimental
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium Hydroxide.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium Hydroxide.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium Hydroxide.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium Hydroxide.Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium Hydroxide.Approved, Vet Approved
ChlorphentermineMagnesium Hydroxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineMagnesium Hydroxide can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineMagnesium Hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineMagnesium Hydroxide can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium Hydroxide.Approved, Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium Hydroxide.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Magnesium Hydroxide.Approved
CinoxacinMagnesium Hydroxide can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
CisatracuriumMagnesium Hydroxide may increase the neuromuscular blocking activities of Cisatracurium.Experimental
Cisatracurium besylateMagnesium Hydroxide may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium Hydroxide.Approved
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Magnesium Hydroxide.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium Hydroxide.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Magnesium Hydroxide.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magnesium Hydroxide.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Magnesium Hydroxide.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Magnesium Hydroxide.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Magnesium Hydroxide.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium Hydroxide.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium Hydroxide.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium Hydroxide.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium Hydroxide.Approved
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Magnesium Hydroxide.Experimental
DasatinibMagnesium Hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DecamethoniumMagnesium Hydroxide may increase the neuromuscular blocking activities of Decamethonium.Approved
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium Hydroxide.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium Hydroxide.Approved
DemeclocyclineMagnesium Hydroxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magnesium Hydroxide.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Magnesium Hydroxide.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium Hydroxide.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium Hydroxide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Magnesium Hydroxide.Vet Approved
DexmethylphenidateMagnesium Hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineMagnesium Hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionMagnesium Hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magnesium Hydroxide.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magnesium Hydroxide.Approved
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magnesium Hydroxide.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Magnesium Hydroxide.Approved
Dipotassium phosphateThe serum concentration of Dipotassium phosphate can be decreased when it is combined with Magnesium Hydroxide.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium Hydroxide.Approved
Domoic AcidMagnesium Hydroxide may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Magnesium Hydroxide.Investigational
Doxacurium chlorideMagnesium Hydroxide may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxycyclineMagnesium Hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium Hydroxide.Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium Hydroxide.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Magnesium Hydroxide.Approved
EnoxacinMagnesium Hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Magnesium Hydroxide.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Magnesium Hydroxide.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Magnesium Hydroxide.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium Hydroxide.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Magnesium Hydroxide.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium Hydroxide.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium Hydroxide.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium Hydroxide.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Magnesium Hydroxide.Withdrawn
Ferric CarboxymaltoseMagnesium Hydroxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateMagnesium Hydroxide can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateMagnesium Hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium Hydroxide.Approved
FleroxacinMagnesium Hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
fluasteroneThe bioavailability of fluasterone can be decreased when combined with Magnesium Hydroxide.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium Hydroxide.Approved
FlumequineMagnesium Hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magnesium Hydroxide.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium Hydroxide.Approved
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium Hydroxide.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium Hydroxide.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magnesium Hydroxide.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magnesium Hydroxide.Approved
FluphenazineMagnesium Hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magnesium Hydroxide.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Magnesium Hydroxide.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium Hydroxide.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Magnesium Hydroxide.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium Hydroxide.Approved
GabapentinMagnesium Hydroxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
GallamineMagnesium Hydroxide may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideMagnesium Hydroxide may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Magnesium Hydroxide.Investigational
GarenoxacinMagnesium Hydroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinMagnesium Hydroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Magnesium Hydroxide.Approved, Investigational
GemifloxacinMagnesium Hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineMagnesium Hydroxide may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinMagnesium Hydroxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Magnesium Hydroxide.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium Hydroxide.Approved, Vet Approved
HydroxyamphetamineMagnesium Hydroxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium Hydroxide.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Hydroxide.Approved, Investigational
Iofetamine I-123Magnesium Hydroxide may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronMagnesium Hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMagnesium Hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateMagnesium Hydroxide can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidMagnesium Hydroxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium Hydroxide.Approved
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Magnesium Hydroxide.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium Hydroxide.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Magnesium Hydroxide.Approved, Investigational
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium Hydroxide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium Hydroxide.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Magnesium Hydroxide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium Hydroxide.Approved, Investigational
LevofloxacinMagnesium Hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium Hydroxide.Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Magnesium Hydroxide.Experimental
Lipoic AcidMagnesium Hydroxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LisdexamfetamineMagnesium Hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium Hydroxide.Approved, Investigational
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium Hydroxide.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Manidipine is combined with Magnesium Hydroxide.Approved
ME-609The bioavailability of ME-609 can be decreased when combined with Magnesium Hydroxide.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium Hydroxide.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magnesium Hydroxide.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Magnesium Hydroxide.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Magnesium Hydroxide.Approved, Investigational
MephedroneMagnesium Hydroxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineMagnesium Hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium Hydroxide.Approved
MesoridazineMagnesium Hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethamphetamineMagnesium Hydroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium Hydroxide.Approved, Vet Approved
MethotrimeprazineMagnesium Hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethoxyphenamineMagnesium Hydroxide may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueMagnesium Hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MethylphenidateMagnesium Hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium Hydroxide.Approved, Vet Approved
MetocurineMagnesium Hydroxide may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideMagnesium Hydroxide may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium Hydroxide.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium Hydroxide.Withdrawn
MidomafetamineMagnesium Hydroxide may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a higher serum level.Experimental, Illicit
MinocyclineMagnesium Hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Magnesium Hydroxide is combined with Misoprostol.Approved
MivacuriumMagnesium Hydroxide may increase the neuromuscular blocking activities of Mivacurium.Approved
MMDAMagnesium Hydroxide may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MoricizineMagnesium Hydroxide can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium Hydroxide.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Magnesium Hydroxide.Investigational
Nalidixic AcidMagnesium Hydroxide can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Magnesium Hydroxide.Investigational
NemonoxacinMagnesium Hydroxide can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NeosaxitoxinMagnesium Hydroxide may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium Hydroxide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium Hydroxide.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium Hydroxide.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium Hydroxide.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Magnesium Hydroxide.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium Hydroxide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium Hydroxide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium Hydroxide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium Hydroxide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Hydroxide.Approved
NorfloxacinMagnesium Hydroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Magnesium Hydroxide.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Magnesium Hydroxide.Experimental
Oxolinic acidMagnesium Hydroxide can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium Hydroxide.Approved
PancuroniumMagnesium Hydroxide may increase the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magnesium Hydroxide.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium Hydroxide.Approved
PazufloxacinMagnesium Hydroxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinMagnesium Hydroxide can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Magnesium Hydroxide.Approved
PerazineMagnesium Hydroxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium Hydroxide.Approved
PerphenazineMagnesium Hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineMagnesium Hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Magnesium Hydroxide.Approved
PipecuroniumMagnesium Hydroxide may increase the neuromuscular blocking activities of Pipecuronium.Approved
Pipemidic acidMagnesium Hydroxide can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidMagnesium Hydroxide can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Magnesium Hydroxide.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Magnesium Hydroxide.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium Hydroxide.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium Hydroxide.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium Hydroxide.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Magnesium Hydroxide.Approved, Illicit, Investigational
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Magnesium Hydroxide.Experimental
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium Hydroxide.Withdrawn
ProchlorperazineMagnesium Hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineMagnesium Hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineMagnesium Hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropiopromazineMagnesium Hydroxide can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinMagnesium Hydroxide can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineMagnesium Hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
PyrantelMagnesium Hydroxide may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinidineMagnesium Hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Magnesium Hydroxide.Approved
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium Hydroxide.Approved
RapacuroniumMagnesium Hydroxide may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Magnesium Hydroxide.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magnesium Hydroxide.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Magnesium Hydroxide.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Hydroxide.Approved, Investigational
RitobegronMagnesium Hydroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RocuroniumMagnesium Hydroxide may increase the neuromuscular blocking activities of Rocuronium.Approved
RosoxacinMagnesium Hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
RufloxacinMagnesium Hydroxide can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
SitafloxacinMagnesium Hydroxide can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium glycerophosphateThe serum concentration of Sodium glycerophosphate can be decreased when it is combined with Magnesium Hydroxide.Approved
Sodium phosphateThe serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium Hydroxide.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium Hydroxide.Approved
SparfloxacinMagnesium Hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Magnesium Hydroxide.Approved
SuccinylcholineMagnesium Hydroxide may increase the neuromuscular blocking activities of Succinylcholine.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium Hydroxide.Approved
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Magnesium Hydroxide.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Magnesium Hydroxide.Approved
TemafloxacinMagnesium Hydroxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Magnesium Hydroxide.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Magnesium Hydroxide.Investigational
ThiazinamMagnesium Hydroxide can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineMagnesium Hydroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioridazineMagnesium Hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium Hydroxide.Approved, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magnesium Hydroxide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Magnesium Hydroxide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium Hydroxide.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magnesium Hydroxide.Approved, Vet Approved
TriethylenetetramineMagnesium Hydroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineMagnesium Hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineMagnesium Hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinMagnesium Hydroxide can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
TubocurarineMagnesium Hydroxide may increase the neuromuscular blocking activities of Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium Hydroxide.Experimental
VecuroniumMagnesium Hydroxide may increase the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium Hydroxide.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Magnesium Hydroxide.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium Hydroxide.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium Hydroxide.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium Hydroxide.Approved
Food Interactions
Not Available

References

General References
  1. Wikipedia [Link]
  2. Drugs.com [Link]
  3. Glow [Link]
  4. Medicines [Link]
  5. Drugs.com [Link]
External Links
KEGG Compound
C07876
PubChem Compound
73981
PubChem Substance
310265028
ChemSpider
14107
ChEBI
6637
ChEMBL
CHEMBL1200718
ATC Codes
A02AA04 — Magnesium hydroxideG04BX01 — Magnesium hydroxide
AHFS Codes
  • 56:04.00 — Antacids and Adsorbents
  • 84:24.12 — Basic Ointments and Protectants
  • 56:12.00 — Cathartics and Laxatives
  • 84:24.00 — Emollients Demulcents and Protectants

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentChronic Kidney Disease (CKD) / Hypomagnesaemia1
2CompletedNot AvailableAcid Reflux Disease / GERD / Heartburn / Regurgitation1
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedTreatmentEmergency / Indigestion / Pain1
Not AvailableCompletedPreventionPost Procedural Constipation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
OintmentTopical.25 %
OintmentTopical0.25 %
GelOral
Tablet, chewableOral
SuspensionOral1200 mg/15mL
SuspensionOral80 mg/mL
SolutionOral
TabletOral
LiquidOral
SuspensionOral
TabletOral385 mg
LiquidOral400 mg/5mL
EmulsionOral
ConcentrateOral2400 mg/10mL
LiquidOral400 mg
SuspensionOral2400 mg/30mL
SuspensionOral2400 mg/10mL
SuspensionOral400 mg/5mL
SuspensionOral7.75 %
LiquidOral8 g
LiquidOral1200 mg/15mL
TabletOral300 mg
SuspensionOral400 mg
SuspensionOral80 mg
SuspensionOral440 mg
Tablet, chewableOral400 mg/1
LiquidOral80 mg
Tablet, chewableOral311 mg/1
LiquidOral2400 mg/15mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6489346No1996-07-162016-07-16Us
US6699885No1996-07-162016-07-16Us
US6645988No1996-07-162016-07-16Us
US7399772No1996-07-162016-07-16Us
US6814978Yes2002-02-262022-02-26Us
US5989588Yes1998-03-302018-03-30Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.57ChemAxon
pKa (Strongest Acidic)15.7ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal oxoanionic compounds
Sub Class
Alkaline earth metal hydroxides
Direct Parent
Alkaline earth metal hydroxides
Alternative Parents
Inorganic salts / Inorganic oxides / Inorganic hydrides
Substituents
Alkaline earth metal hydroxide / Inorganic hydride / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
magnesium hydroxide (CHEBI:6637)

Drug created on September 16, 2015 16:26 / Updated on October 23, 2017 14:13